JP6708544B2 - 新規抗体フレームワーク - Google Patents

新規抗体フレームワーク Download PDF

Info

Publication number
JP6708544B2
JP6708544B2 JP2016522319A JP2016522319A JP6708544B2 JP 6708544 B2 JP6708544 B2 JP 6708544B2 JP 2016522319 A JP2016522319 A JP 2016522319A JP 2016522319 A JP2016522319 A JP 2016522319A JP 6708544 B2 JP6708544 B2 JP 6708544B2
Authority
JP
Japan
Prior art keywords
antigen
sequence
framework
human
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016522319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523537A5 (show.php
JP2016523537A (ja
Inventor
マイアー ゼバスティアン
マイアー ゼバスティアン
ウレヒ ダービト
ウレヒ ダービト
Original Assignee
ヌマブ セラピューティクス アクチェンゲゼルシャフト
ヌマブ セラピューティクス アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌマブ セラピューティクス アクチェンゲゼルシャフト, ヌマブ セラピューティクス アクチェンゲゼルシャフト filed Critical ヌマブ セラピューティクス アクチェンゲゼルシャフト
Publication of JP2016523537A publication Critical patent/JP2016523537A/ja
Publication of JP2016523537A5 publication Critical patent/JP2016523537A5/ja
Application granted granted Critical
Publication of JP6708544B2 publication Critical patent/JP6708544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2016522319A 2013-06-26 2014-06-26 新規抗体フレームワーク Active JP6708544B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003264 2013-06-26
EP13003264.2 2013-06-26
PCT/EP2014/001730 WO2014206561A1 (en) 2013-06-26 2014-06-26 Novel antibody frameworks

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019111990A Division JP2019201643A (ja) 2013-06-26 2019-06-17 新規抗体フレームワーク

Publications (3)

Publication Number Publication Date
JP2016523537A JP2016523537A (ja) 2016-08-12
JP2016523537A5 JP2016523537A5 (show.php) 2018-01-18
JP6708544B2 true JP6708544B2 (ja) 2020-06-10

Family

ID=48699516

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016522319A Active JP6708544B2 (ja) 2013-06-26 2014-06-26 新規抗体フレームワーク
JP2019111990A Withdrawn JP2019201643A (ja) 2013-06-26 2019-06-17 新規抗体フレームワーク
JP2021169020A Pending JP2022028659A (ja) 2013-06-26 2021-10-14 新規抗体フレームワーク
JP2023199881A Pending JP2024026176A (ja) 2013-06-26 2023-11-27 新規抗体フレームワーク

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019111990A Withdrawn JP2019201643A (ja) 2013-06-26 2019-06-17 新規抗体フレームワーク
JP2021169020A Pending JP2022028659A (ja) 2013-06-26 2021-10-14 新規抗体フレームワーク
JP2023199881A Pending JP2024026176A (ja) 2013-06-26 2023-11-27 新規抗体フレームワーク

Country Status (12)

Country Link
US (3) US10174102B2 (show.php)
EP (1) EP3013864A1 (show.php)
JP (4) JP6708544B2 (show.php)
KR (4) KR20220029763A (show.php)
CN (2) CN105579472B (show.php)
AU (2) AU2014301629B2 (show.php)
CA (1) CA2914829A1 (show.php)
HK (1) HK1218549A1 (show.php)
IL (3) IL243311B (show.php)
NZ (1) NZ714320A (show.php)
SG (2) SG10201811017QA (show.php)
WO (1) WO2014206561A1 (show.php)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201811017QA (en) 2013-06-26 2019-01-30 Numab Innovation Ag Novel antibody frameworks
CN107922486B (zh) 2015-06-15 2022-05-31 努玛治疗有限公司 异源二聚体多特异性抗体形式
WO2017144681A1 (en) 2016-02-25 2017-08-31 Cell Medica Switzerland Ag Binding members to pd-l1
LT3219726T (lt) 2016-03-17 2021-01-25 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
EP3430042B1 (en) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnfalpha-antibodies and functional fragments thereof
WO2017158079A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnfalpha-antibodies and functional fragments thereof
LT3219727T (lt) 2016-03-17 2021-02-10 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
JP6978427B2 (ja) 2016-03-17 2021-12-08 ヌマブ セラピューティクス アクチェンゲゼルシャフト 抗ＴＮＦα抗体とその機能性フラグメント
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US12098203B2 (en) 2017-06-05 2024-09-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
EP3634998B8 (en) 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
KR102754842B1 (ko) * 2017-06-05 2025-01-17 누맙 세러퓨틱스 아게 신규 항 hsa 항체
KR20250024104A (ko) 2017-06-25 2025-02-18 시스트이뮨, 인코포레이티드 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
JP7474193B2 (ja) * 2017-06-25 2024-04-24 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
CA3127935A1 (en) 2019-01-31 2020-08-06 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP4271413A4 (en) * 2020-12-30 2025-07-30 Ascendo Biotechnology Inc MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND ITS USES
US20220259296A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
JP2024509971A (ja) 2021-03-11 2024-03-05 アイジェニックス， インコーポレイテッド アレルギー応答を予測するための方法およびシステム
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases
EP4611774A2 (en) * 2022-11-04 2025-09-10 MiNK Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
CA2688829A1 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Novel rabbit antibody humanization methods and humanized rabbit antibodies
EP2158315B1 (en) 2007-06-25 2016-03-23 ESBATech, an Alcon Biomedical Research Unit LLC Methods of modifying antibodies, and modified antibodies with improved functional properties
EP2307458B1 (en) * 2008-06-25 2018-04-11 ESBATech, an Alcon Biomedical Research Unit LLC Humanization of rabbit antibodies using a universal antibody framework
ES2793008T3 (es) * 2008-06-25 2020-11-12 Novartis Ag Anticuerpos estables y solubles que inhiben VEGF
HUE053548T2 (hu) 2008-06-25 2021-07-28 Novartis Ag Stabil és szolúbilis, TNF-gátló ellenanyagok
WO2010144780A1 (en) 2009-06-12 2010-12-16 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
SG185107A1 (en) * 2010-04-30 2012-12-28 Alexion Pharma Inc Antibodies having reduced immunogenicity in a human
WO2012163519A1 (en) * 2011-05-27 2012-12-06 Dutalys Antibodies with improved folding stability
SG10201811017QA (en) 2013-06-26 2019-01-30 Numab Innovation Ag Novel antibody frameworks
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations

Also Published As

Publication number Publication date
JP2019201643A (ja) 2019-11-28
IL243311B (en) 2022-07-01
KR102286053B1 (ko) 2021-08-04
US10174102B2 (en) 2019-01-08
KR20210097829A (ko) 2021-08-09
SG10201811017QA (en) 2019-01-30
HK1218549A1 (zh) 2017-02-24
IL293477B2 (en) 2024-11-01
WO2014206561A8 (en) 2016-02-18
KR20240000622A (ko) 2024-01-02
IL293477B1 (en) 2024-07-01
US20230212265A1 (en) 2023-07-06
US20190119359A1 (en) 2019-04-25
EP3013864A1 (en) 2016-05-04
CN105579472A (zh) 2016-05-11
JP2022028659A (ja) 2022-02-16
NZ714320A (en) 2022-02-25
CN113943366A (zh) 2022-01-18
AU2014301629B2 (en) 2020-02-06
KR20160024923A (ko) 2016-03-07
CN113943366B (zh) 2024-12-13
IL313351A (en) 2024-08-01
KR20220029763A (ko) 2022-03-08
US20160130326A1 (en) 2016-05-12
CN105579472B (zh) 2021-10-22
WO2014206561A1 (en) 2014-12-31
SG11201509899PA (en) 2016-01-28
AU2020202770A1 (en) 2020-05-14
JP2024026176A (ja) 2024-02-28
JP2016523537A (ja) 2016-08-12
CA2914829A1 (en) 2014-12-31
AU2014301629A1 (en) 2015-12-10
IL243311A0 (en) 2016-03-31
AU2020202770B2 (en) 2023-01-05
IL293477A (en) 2022-08-01
US11427628B2 (en) 2022-08-30
IL313351B1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
JP6708544B2 (ja) 新規抗体フレームワーク
JP2016523537A5 (show.php)
JP2023115024A (ja) 新規の安定した抗体の可変領域フレームワークの組み合わせ
AU2012265156B2 (en) Dual targeting
US10738103B2 (en) Antibody light chains
US11365240B2 (en) Anti-HSA antibodies
CN104981482A (zh) 双靶向作用
Ebrahimi et al. Nanobody as a new generation of functional proteins
HK1205145B (en) Improved antibody light chains

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200521

R150 Certificate of patent or registration of utility model

Ref document number: 6708544

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250